Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1953

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1C
Chunk 1953
---
 (111,689) 
     (80.7)%
  
    Total other income, net 
     7,893,613  
     385,472  
     7,508,140  
     1,947.78%

    Net loss 
     (8,304,423) 
     (7,289,577) 
     (1,014,846) 
     13.9%
  
    Deemed dividend 
     (2,784,839) 
     -  
     (2,784,839) 
     - 
  
    Net loss attributable to common stockholders 
    $(11,089,262) 
    $(7,289,577) 
    $(3,799,686) 
     52.1%

General and Administrative Expenses

General and administrative expenses were $9.1 million for the year
ended December 31, 2024, compared to $2.4 million for the year ended December 31, 2023, reflecting an increase of $6.7 million. The increase
in the year ended December 31, 2024, over the year ended December 31, 2023, was partially due to a $1.8 million expense consisting of
the remaining underwriting fees from the PBAX initial public offering, which were earned on the consummation of the business combination.
Additionally, the hiring of senior management in G&A resulted in an increase of $2.0 million, including recruiting fees. Legal fees
increased $1.0 million and business consulting increased $0.8 million in the year ended December 31, 2024, versus the year ended December
31, 2023. Expenses related to services required for SEC compliance, such as printing and transfer agency fees, increased $0.5 million
and public company insurance coverage increased insurance expenses $0.5 million in the year ended December 31, 2024, compared to the year
ended December 31, 2023. Corporate communications and director fees each increased $0.2 million in the year ended December 31, 2024 compared
to the year ended December 31, 2023. The additional expenses are all driven by the increased expenses of operational compliance as a public
company.

105

Research and Development Expenses

Research and development
expenses were $7.6 million for the year ended December 31,